This Distribution Agreement is entered into by Meditek Pharma and Genomix Inc., effective April 15, 2025.

Meditek agrees to share 5% of net revenue from licensed products with Genomix for every quarter.

Post-termination, Genomix shall assist in the transfer of licensing rights to any successor.

The Agreement shall remain in effect for 2 years and may be terminated for convenience by either party with 30 days' written notice.

Governing law: State of New York.